Teprotumumab biosimilar(Boxiao Bio-pharma)

替妥木单抗生物类似药（博崤生物）

Report date: 2024/05/21 10:43:46
First In Class

Base Information

Drug NameTeprotumumab biosimilar(Boxiao Bio-pharma)
Drug Alias Name替妥尤单抗生物类似药（博崤生物）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsGraves Ophthalmopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Boxiao Bio-pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Boxiao Bio-pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGraves Ophthalmopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG